newsfilter
← Latest News
GlobeNewswire·

MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer

  • MAIA Biotechnology announced updated interim efficacy data from Part C of the Phase 2 THIO-101 trial for ateganosine in advanced non-small cell lung cancer (NSCLC).
  • The drug has received FDA Fast Track designation, with new data potentially supporting an accelerated approval filing.
  • THIO-101 Part C evaluates ateganosine as a third-line treatment for patients who progressed after prior immune checkpoint inhibitor & chemotherapy.
  • The treatment protocol involves sequential administration of 180mg ateganosine followed by cemiplimab (Libtayo) in 21-day cycles.
  • An 88% disease control rate (DCR) was observed in the efficacy-evaluable population of Part C (38 of 43 patients) as of October 1, 2026.
  • This 88% DCR contrasts with the 25%–35% rate typically seen in standard third-line chemotherapy regimens.
  • MAIA completed enrollment in Part C across multiple countries including the United States, Hungary, Poland, Turkey, Georgia, Romania, & Taiwan.
  • The ongoing pivotal Phase 3 trial (THIO-104) for the same patient population is advancing toward a 2027 interim survival analysis.
  • Ateganosine is a first-in-class telomere-targeting agent that induces cancer cell death & activates innate & adaptive immune responses.
  • Forward-looking statements regarding regulatory milestones, trial progress, & market acceptance are included in the press release.
Company
MAIA Biotechnology, Inc.
Keywords
NYSE:MAIA, MAIA Biotechnology, Inc., MAIA Biotechnology, Inc., NYSE American: MAIA, clinical-stage, biopharmaceutical company, Non-Small Cell Lung Cancer, THIO-101